McCurdy Lewis H, Larkin Brenda D, Martin Julie E, Graham Barney S
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3017, USA.
Clin Infect Dis. 2004 Jun 15;38(12):1749-53. doi: 10.1086/421266. Epub 2004 May 19.
Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. Although the currently available vaccine was used for the most successful medical intervention ever accomplished, it also is associated with side effects that are difficult to accept in a vaccine for a disease that has not been present for >25 years. Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine.
尽管1980年宣布根除天花,但天花病毒库存的存在以及生物恐怖主义的威胁要求通过接种疫苗维持对天花的免疫力。虽然目前可用的疫苗用于有史以来最成功的医学干预,但它也伴有一些副作用,而对于一种已消失超过25年的疾病的疫苗来说,这些副作用难以让人接受。在此,我们综述了通过接种减毒痘病毒来维持对天花免疫力的替代方法,并建议将安卡拉痘苗病毒(MVA)作为替代天花疫苗的主要候选疫苗。